Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Inhibition of TRPV1 by SHP-1 in nociceptive primary sensory neurons is critical in PD-L1 analgesia
Ben-Long Liu, Qi-Lai Cao, Xin Zhao, Hui-Zhu Liu, Yu-Qiu Zhang
Ben-Long Liu, Qi-Lai Cao, Xin Zhao, Hui-Zhu Liu, Yu-Qiu Zhang
View: Text | PDF
Research Article Neuroscience

Inhibition of TRPV1 by SHP-1 in nociceptive primary sensory neurons is critical in PD-L1 analgesia

  • Text
  • PDF
Abstract

Recently programmed death-ligand 1 (PD-L1) receptor PD-1 was found in dorsal root ganglion (DRG) neurons, and PD-L1 activates PD-1 to inhibit inflammatory and neuropathic pain by modulating neuronal excitability. However, the downstream signaling of PD-1 in sensory neurons remains unclear. Here, we show that PD-L1 activated Src homology 2 domain-containing tyrosine phosphatase-1 (SHP-1) to downregulate transient receptor potential vanilloid 1 (TRPV1) in DRG neurons and inhibit bone cancer pain in mice. Local injection of PD-L1 produced analgesia. PD-1 in DRG neurons colocalized with TRPV1 and SHP-1. PD-L1 induced the phosphorylation of SHP-1 in DRG TRPV1 neurons and inhibited TRPV1 currents. Loss of TRPV1 in mice abolished bone cancer–induced thermal hyperalgesia and PD-L1 analgesia. Conditioned deletion of SHP-1 in NaV1.8+ neurons aggravated bone cancer pain and diminished the inhibition of PD-L1 on TRPV1 currents and pain. Together, our findings suggest that PD-L1/PD-1 signaling suppresses bone cancer pain via inhibition of TRPV1 activity. Our results also suggest that SHP-1 in sensory neurons is an endogenous pain inhibitor and delays the development of bone cancer pain via suppressing TRPV1 function.

Authors

Ben-Long Liu, Qi-Lai Cao, Xin Zhao, Hui-Zhu Liu, Yu-Qiu Zhang

×

Figure 5

PD-L1 inhibits TRPV1 via SHP-1.

Options: View larger image (or click on image) Download as PowerPoint
PD-L1 inhibits TRPV1 via SHP-1.
(A) Schematic illustration of SHP-1–CKO ...
(A) Schematic illustration of SHP-1–CKO mice by Cre-Lox system crossing SHP-1fl/fl mice with NaV1.8-Cre mice. (B) Double immunofluorescence reveals colocalization of Nav1.8 and SHP-1 in the L4 DRG of control mice but no double staining signal of SHP-1 and NaV1.8 in the L4 DRG of SHP-1 CKO (bottom). Scale bar: 50 μm. (C) Western blot analysis showing a significant reduction of SHP-1 in the L3–L5 DRGs of CKO mice. *P < 0.05 versus littermate controls, 2-tailed Student’s t test; n = 5 control and 4 SHP-1–CKO (mice). (D) Traces showing that PD-L1 suppresses 1.5 μM capsaicin–evoked TRPV1 currents in DRG neurons of littermate control mice (upper) but not in SHP-1–CKO mice (bottom). (E) Quantification of changes in TRPV1 current density in DRG neurons of SHP-1–CKO and littermate control mice. *P < 0.05, **P < 0.01 versus vehicle control; 1-way ANOVA followed by post hoc Student-Newman-Keuls test; n = 27 SHP-1fl/fl vehicle, 14 SHP-1fl/fl PD-L1, 23 NaV1.8-Cre vehicle, and 15 NaV1.8-Cre PD-L1 (cells). (F) KO of SHP-1 in NaV1.8+ neurons was confirmed by intracellular Lucifer dye injection and immunocytochemistry staining (NaV1.8 and SHP-1) after recording.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts